Harish Krishnamoorthy is one of four fellows recognized by the program — and the first from UH to receive the honor. Photo via UH.edu

A University of Houston professor has been selected by a national organization to “contribute to the understanding, management and reduction of systemic risk in offshore energy activities.”

The Gulf Research Program of the National Academies of Sciences, Engineering, and Medicine announced that Harish Krishnamoorthy, assistant professor of electrical and computer engineering at the University of Houston, is one of four selected early-career research fellows in the Offshore Energy Safety track. Krishnamoorthy is the first researcher from UH selected for the recognition.

“I am happy and honored to be the first one, but hopefully there will be a lot more in the coming years,” Krishnamoorthy says in a UH news release.

The award, which isn't granted based on a specific project, includes a $76,000 grant, mentor support, and access to a network of current and past cohorts.

Created in 2013, the program is an independent, science-based program founded as part of legal settlements with the companies involved in the 2010 Deepwater Horizon disaster. Its goal is "to enhance offshore energy system safety and protect human health and the environment by catalyzing advances in science, practice and capacity, generating long-term benefits for the Gulf of Mexico region and the nation," the release reads.

“These exceptional individuals are working hard to pursue new research, technical capabilities, and approaches that address some of the greatest challenges facing the Gulf and Alaska regions today,” says Karena Mary Mothershed, senior program manager for the Gulf Research Program’s Board on Gulf Education and Engagement. “We are incredibly excited to announce these new Early-Career Research Fellows, and to continue supporting them as they make lasting impacts.”

Krishnamoorthy, who also serves as associate director of the Power Electronics, Microgrids and Subsea Electric Systems Center at UH, has expertise is in power electronics, power converters, and offshore technologies. His research interests include high-density power conversion for grid interface of energy systems, machine learning-based methods for improvement in quality and reliability of power electronics, advanced electronics and control for mission-critical applications.

According to Krishnamoorthy, there are around 1,500 offshore rigs — with a large amount located North Sea and the Gulf of Mexico. There's a need to improve existing systems, according to Krishnamoorthy, and this process of evolving the grid comes with safety risks and challenges.

“When there are so many electronics involved, safety and reliability are going to be very critical,” Krishnamoorthy says in he release. “I have been looking at safety aspects a lot in my research as well as how to connect subsea oil and gas systems with offshore renewable systems.”

In 2022, Krishnamoorthy was recognized as an OTC Emerging Leader at the Offshore Technology Conference for his contributions to offshore safety and workforce development in offshore, as well as reducing the carbon emissions.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”